SCHEMBL22116306

SCHEMBL22116306

Cc1ccc([C@H]2CC[C@H](O)CC2)c(OC2(C(=O)O)CC2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 1/20 0.39
▸ DRD4 P21917 4/20 0.36
▸ SLC6A2 P23975 3/20 0.36
▸ SLC6A4 P31645 3/20 0.36
▸ SLC6A3 Q01959 3/20 0.36
▸ HTT P42858 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ DRD2 P14416 2/20 0.34
▸ KDM4C Q9H3R0 1/20 0.33
▸ PPARD Q03181 3/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ SLC22A12 Q96S37 1/20 0.32
▸ PPARA Q07869 1/20 0.32
▸ DRD3 P35462 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ JAK2 O60674 1/20 0.31
▸ JAK1 P23458 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22116308 1.00 PTGDR2 (0.39) PTGDR2DRD4SLC6A2SLC6A4SLC6A3
SCHEMBL22116403 0.95 PTGDR2 (0.42) PTGDR2DRD4SLC6A2SLC6A4SLC6A3
SCHEMBL22116341 0.93 GCK (0.37) PTGDR2DRD4SLC6A2SLC6A4SLC6A3
SCHEMBL22116357 0.90 PTGDR2 (0.49) PTGDR2SLC6A2SLC6A4SLC6A3LMNA
SCHEMBL22116359 0.89 PTGDR2 (0.38) PTGDR2DRD4SLC6A2SLC6A4SLC6A3
SCHEMBL22116360 0.89 PTGDR2 (0.38) PTGDR2DRD4SLC6A2SLC6A4SLC6A3
SCHEMBL22116418 0.89 PTGDR2 (0.38) PTGDR2DRD4SLC6A2SLC6A4SLC6A3
SCHEMBL24234234 0.88 PTGDR2 (0.51) PTGDR2SLC6A2SLC6A4SLC6A3LMNA
SCHEMBL22116373 0.88 PTGDR2 (0.51) PTGDR2SLC6A2SLC6A4SLC6A3LMNA
SCHEMBL22116338 0.86 PTGDR2 (0.38) PTGDR2DRD4SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3897832-A1 N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE Novartis AG (CH) 2021-10-27 — — EP disclosed
WO-2020128768-A1 N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE NOVARTIS AG (CH) 2020-06-25 — — WO disclosed
Send feedback